Abstract: A method for treating, attenuating or inhibiting an infection and/or disease associated with a SARS virus in a subject is provided that includes administering a pharmaceutical composition to the subject. The composition includes an organosilicone carrier with one or more active substances that block and/or inhibit an ACE2 receptor in a host cell of the subject, the spike protein of a SARS virus and/or internal components of a virion of the SARS virus.

Abstract: A method for treating, attenuating or inhibiting an infection and/or disease associated with a SARS virus in a subject is provided that includes administering a pharmaceutical composition to the subject. The composition includes an organosilicone carrier with one or more active substances that block and/or inhibit an ACE2 receptor in a host cell of the subject, the spike protein of a SARS virus and/or internal components of a virion of the SARS virus.

Abstract: A pharmaceutical compositions including proline or proline derivatives is provided. A method for the treatment of dementia, Alzheimer's and neurodegenerative diseases with the compositions is also provided.

Abstract: A pharmaceutical compositions including proline or proline derivatives is provided. A method for the treatment of dementia, Alzheimer's and neurodegenerative diseases with the compositions is also provided.

Abstract: The present invention relates to methods and compositions for the treatment of pain, in a preferred embodiment relating to the oral transmucosal administration of S-Ketamine, its salts or derivatives.

Abstract: The invention relates to a novel organosilicon carrier system for biological agents that is produced via a simple, stable and reproducible preparation process that is capable of maintaining tertiary protein structure and biological activity of the proteins and/or other biological agents in the mixture, whereby the carrier system is obtainable by mixing one or more organosilicon compounds, selected from the group comprising organosilicon, sugar organosilicon, amino sugar organosilicon compounds, their derivatives, salts and/or the vesicles formed from them, with one or more biological agents, selected from the group comprising antigens, preantigens, antigen conjugates, antibodies, pre-antibodies, antibody conjugates, allergens, allergen extracts, nucleic acids, plasmids, proteins, peptides, pharmaceutical agents, immunologically active substances and/or cosmetics, in solution at a pH value between 7 and 8, preferably 7.

Abstract: The invention relates to a pharmaceutical agent, particularly a chemotherapeutical agent, comprising cis-diammoniumdichloro-trans-dihydroxoplatinum(IV) or salts and/or derivatives thereof in the form of capsules, tablets, creams, ointments and infusion solutions, and to the production of said pharmaceutical agent; the invention also relates to the use of such pharmaceutical agents in the treatment of tumor diseases.

Abstract: The present invention relates to a pharmaceutical composition comprising of proline or proline derivatives or their salts, esters, isomers, racemates, enantiomeres or prodrugs together with an anti-cancer ligand, preferably an antibody directed to a tumour antigen. The invention is also directed to the use of proline or proline derivatives or their salts, esters, isomers or prodrugs for the manufacture of a pharmaceutical composition for treating cancer and to a method of cancer treatment by administering said composition.

Abstract: The invention relates to a method for the preparation of trans- or cis-diammoniumdichlorodihydroxoplatinum(IV) and derivatives thereof. What is suggested is reacting trans- or cis-diammoniumdichloroplatinum(II) with a solution comprising >30% peroxide at temperatures below 30° C. and dissolving the product thus obtained in a mineral acid and subsequently precipitating with an alkaline solution.

Abstract: The invention relates to a composition of proteins, peptides and/or peptide components, a pharmaceutical agent comprising said composition, a method for the production of said composition and the use thereof in the prophylaxis or therapy of persons, animals and/or patients with pathogenic modifications and/or cellular immunodeficiencies, especially cancer, septicemia or allergic reactions, in connection with a cytostatic agent therapy, chemotherapy and/or radiotherapy.

Abstract: The invention relates to proline derivatives and their salts, to pharmaceutical agents containing said derivatives and to the use of said agents for treating tumours. The invention also relates to methods for producing said compounds and pharmaceutical agents.

Abstract: The invention relates to novel chelidonine derivatives, methods for the production thereof, the use of said compounds for the prevention, treatment, monitoring of the progress, and aftertreatment of diseases related to cell growth, cell differentiation, and/or cell division, especially tumors, and a kit comprising the inventive chelidonine derivatives.

Abstract: A system for the controlled release of an active agent to an environment of use, said system having a predetermined release rate of the active agent to the environment of use, comprising: a) a shell comprised of a wall formed of a water-insoluble material which is permeable to the passage of an external fluid, and b) a core which is surrounded by said shell, said core comprised of i) a water-soluble active agent, and ii) a soluble polymeric adjuvant capable of unlimited swelling.